以下文章来源于凤凰WEEKLY ，作者面二 凤凰WEEKLY . 有温度、有情感、有趣味 中国三甲医院，批量征服"外国中产"。 文 ｜ 面二 编辑 ｜ 章鱼 来源｜ 凤凰网WEEKLY（ID：phoenixweekly） 封面来源 ｜ IC Photo 来中国旅行，过去一年的外网 流量密码。 外网的" 中国旅游三件套"，甚至经历过两次迭代。 最开始，外网博主们来中国的必打卡项目还是：线上支付、高铁速度、酒店机器人。 这半年， 老外的 中国旅游新三件套 变成了：牙医、眼科、中医理疗。 TikTok的"Medical Tourism（医疗旅游）"的标签下，大批外国人摩拳擦掌准备到中国看病。 而他们的必打卡目的地，也新增了一个 三甲医院。 2024年，深圳为境外人士提供诊疗 服务77万人次，其中包括港澳人士64万人次，其余的则来自美国、加拿大、日本等国家。 上海13家指定医院接诊外籍患者近27万， 同比增长15%。 据国家卫生健康委员会2025年度涉外医疗服务报告显示：国内重点涉外医院全年接诊国际患者达128万人次，较三年前增长73.6%。 来中国边旅游边看病，正在成为一种风靡外网的新潮流。 新一批来中国旅游的外国 ...

（文章来源：证券日报） 证券日报网讯 1月19日，爱尔眼科在互动平台回答投资者提问时表示，工作、生活的手机化持续增加用 眼时长和用眼强度，眼科服务需求实际在逐步扩大。 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Hema Medical (03309.HK) by 10,000 shares on January 8, with a total net reduction of 390,000 shares over the past five trading days and 1,546,000 shares over the past 20 trading days [1] - As of now, southbound funds hold 75,161,000 shares of Hema Medical, which accounts for 6.09% of the company's total issued ordinary shares [1] Group 2 - Hema Medical Holdings Limited, formerly known as Hema Eye Medical Holdings Limited, is primarily engaged in providing medical services through four business segments [2] - The Hong Kong medical business segment focuses on offering ophthalmology, dentistry, and other medical services, as well as selling vision aids [2] - The mainland dental business segment is dedicated to providing dental services in mainland China [2] - The medical consumables sales segment primarily involves selling medical consumables in Hong Kong [2] - The mainland ophthalmology business segment focuses on providing ophthalmology services and selling vision aids in mainland China [2]

Company Overview - Zhuozheng Medical has passed the main board listing hearing at the Hong Kong Stock Exchange, with Haitong International and Puyin International as joint sponsors [1] - As of 2024, Zhuozheng Medical is the third largest private mid-to-high-end comprehensive medical service provider in China, holding a market share of 2.0% [1] Industry Growth - The private mid-to-high-end medical service market in China is experiencing rapid growth, with total revenue increasing from RMB 193 billion in 2020 to RMB 426.3 billion in 2024, and is projected to reach RMB 831.4 billion by 2029 [1] Company Operations - As of October 28, 2025, Zhuozheng Medical operates 19 medical service institutions in 10 economically developed cities in China, including 17 clinics and 2 hospitals, and has 5 general clinics in Singapore and Malaysia [1] - The company employs a family medical model that integrates online and offline services, offering specialized services in pediatrics, dentistry, ophthalmology, and dermatology [1] - As of August 31, 2025, the company has 387 full-time doctors with an average of 15 years of practice experience, of which approximately 79% have worked in top-tier hospitals [1]

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Group 1: Shareholding Changes - On November 6, southbound funds reduced their holdings by 58,000 shares, marking a decrease of 0.07% [2]. - Over the past five trading days, there has been a cumulative net reduction of 1,252,000 shares, with reductions occurring on all five days [1][2]. - In the last twenty trading days, the total net reduction reached 3,934,000 shares, with reductions on all twenty days [1]. Group 2: Current Holdings - As of the latest data, southbound funds hold 77,831,000 shares of Hema Medical, which represents 6.19% of the company's total issued ordinary shares [1][2]. Group 3: Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: Hong Kong medical services, mainland dental services, medical consumables sales, and mainland ophthalmic services [2].

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Summary by Sections Southbound Fund Holdings - On October 22, southbound funds reduced their holdings by 72,000 shares, marking a decrease of 0.09% [2]. - Over the past five trading days, there has been a cumulative net reduction of 634,000 shares, with reductions occurring on all five days [1][2]. - In the last 20 trading days, the total net reduction reached 3,286,000 shares, with reductions on all 20 days [1]. Current Holdings - As of the latest data, southbound funds hold a total of 79,449,000 shares of Hema Medical, which represents 6.32% of the company's total issued ordinary shares [1][2]. Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: - The Hong Kong medical division focuses on ophthalmology, dentistry, and other medical services, as well as the sale of vision aids [2]. - The mainland dental division provides dental services in mainland China [2]. - The medical consumables division sells medical consumables in Hong Kong [2]. - The mainland ophthalmology division offers ophthalmic services and sells vision aids in mainland China [2].

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Summary by Sections Southbound Fund Holdings - On October 15, southbound funds reduced their holdings by 88,000 shares, marking a decrease of 0.11% [2]. - Over the past five trading days, there has been a cumulative net reduction of 1,242,000 shares, with reductions occurring on all five days [1][2]. - In the last 20 trading days, the total net reduction reached 3,440,000 shares, with reductions on all 20 days [1]. Current Holdings - As of now, southbound funds hold 80,083,000 shares of Hema Medical, which represents 6.37% of the company's total issued ordinary shares [1]. Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: - The Hong Kong medical division focuses on ophthalmology, dentistry, and other medical services, along with the sale of vision aids [2]. - The mainland dental division provides dental services in mainland China [2]. - The medical consumables sales division operates in Hong Kong [2]. - The mainland ophthalmology division offers ophthalmic services and sells vision aids in mainland China [2].

SBC Medical Group Holdings Conference Summary Company Overview - SBC Medical Group Holdings Inc. trades on NASDAQ under the symbol SBC and is headquartered in Irvine, California, and Tokyo, Japan. The company provides management services and products to cosmetic treatment centers [4][5]. Core Business and Performance - SBC primarily offers comprehensive management support services to franchise clinics, focusing on aesthetic medicine. The company generates income through franchise fees and has diversified its offerings to include orthopedics, ophthalmology, health treatment, and infertility treatment [5][6]. - The total number of franchise clinics has increased to 259, with a net addition of 36 clinics since the previous year [6]. - Despite severe competition in Japan's aesthetic medicine industry, the number of customers has steadily increased, reaching 6.3 million annually [7]. Financial Performance - In February 2024, SBC began restructuring its business, which included revising franchise fees. This led to an 18% year-on-year decline in total revenue [8]. - Increased point redemption by customers reduced revenue, impacting management service revenues, while procurement and rental revenue rose due to higher purchases of medical materials [9]. - The company acquired MB carrier lounge, adding Zoom clinic to its network, which operates six clinics known for customizable laser treatments [9][10]. Strategic Initiatives - SBC launched NIO Skin Clinic in April, targeting expert-level customers with advanced global treatments, which has quickly gained popularity [12]. - The company is enhancing its medical tourism strategy, particularly focusing on Chinese tourists, by increasing its presence on social media and hosting promotional events [13]. - SBC is concentrating on high-growth areas such as orthopedics and AG treatment, responding to Japan's aging demographics [14]. Management and Global Expansion - The company has strengthened its management structure in the U.S. by hiring experienced professionals from various industries [15][16]. - SBC is committed to expanding its global business, including launching Japanese language services in Singapore [16]. Financial Strategy and Shareholder Returns - SBC maintains a robust financial base with sufficient cash on hand for domestic and global growth, including M&A opportunities [17]. - The company is considering new share issuance and partial sales by the founder to improve liquidity and accessibility for a broader investor base [18]. - SBC conducted its first share buyback program from May to July, which positively contributed to its share price and liquidity [18]. Future Outlook - The company aims to strengthen its core business in Japan while expanding into general medical areas and establishing a solid foundation in the U.S. and Southeast Asia [28]. - SBC plans to balance growth investment with shareholder returns, prioritizing funds for growth while ensuring support from a wider range of investors [25][26]. Key Takeaways - SBC Medical Group Holdings is focused on expanding its aesthetic medicine services while diversifying into other medical fields. - The company is undergoing strategic restructuring to position itself for future growth despite recent revenue declines. - There is significant growth potential in the aesthetic medicine market in Japan, with only about 10% of the population currently utilizing these services [22]. - SBC is actively working on enhancing its brand visibility and liquidity to attract more institutional investors [18].

Group 1 - The company has a total of 38 hospitals in its medical sector, with 32 of them being rehabilitation hospitals focused on severe rehabilitation [2] - The subsidiary Ningbo Mingzhou Hospital is a tertiary Class B comprehensive hospital with over 40 departments, including dental, ophthalmology, and medical aesthetics [2]

Summary of SBC Medical Group Holdings Conference Call Company Overview - SBC Medical Group Holdings operates in the aesthetic medicine sector, providing comprehensive management support services to franchise clinics, generating income through franchise fees [4][5] - The company was successfully listed on the Nasdaq in September 2024, marking a significant milestone in its expansion plans [4] - SBC serves over 6 million patients annually, making it the largest provider in Japan's aesthetic medicine market [5] Financial Performance - Revenue decreased by 14% year-over-year due to business restructuring and currency fluctuations, but excluding these factors, there was a 5% growth [9] - The EBITDA margin stands at 52%, and the annualized Return on Equity (ROE) is 41%, indicating strong profitability [10] - The company maintains a robust balance sheet with a healthy cash position and minimal debt obligations, allowing for strategic growth opportunities [10] Business Strategy - SBC is focusing on a multi-brand strategy to cater to diverse customer needs in aesthetic medicine [7][15] - The company aims to evolve into a global medical services provider by 2027, with a strong emphasis on aesthetic medicine and international expansion [14] - The Japanese market has a penetration rate of around 10%, indicating substantial growth opportunities, particularly among middle-aged women and male customers [15] Pricing Strategy - A major overhaul of the pricing structure was implemented in March 2025 to streamline pricing and improve cost efficiency [11] - Franchise fee structures were revised to alleviate financial burdens on newly opened clinics, promoting long-term sustainability [13] International Expansion - SBC is focusing on the US and Asia for international growth, with plans to establish a presence in the US medical spa market [19] - The company acquired a leading provider in Singapore, marking a key milestone in its Asian expansion strategy [20] - Local market adaptation is crucial for successful international operations, with plans to integrate Japanese expertise selectively [31] New Initiatives - The launch of SBC Wellness, a corporate employee benefit program, aims to meet the growing demand for health-oriented workplace initiatives [21] - A strategic partnership with a leading vertical SaaS provider for aesthetic clinics was announced to enhance operational capabilities [21] Shareholder Value and Capital Policy - The company is considering a share repurchase program to improve liquidity and enhance shareholder value, with an initial approval for a buyback of 5 million shares [22][23] - Additional liquidity measures, including potential secondary offerings, are being evaluated to balance supply and demand in the market [28][29] Market Response - The multi-brand strategy has been well received, with the recent launch of the SBIC NeoSkin Clinic experiencing strong demand and limited appointment availability [34] This summary encapsulates the key points discussed during the SBC Medical Group Holdings conference call, highlighting the company's strategic direction, financial performance, and market initiatives.